HUE052886T2 - Módszerek kolesztázisos és fibrotikus betegségek kezelésére - Google Patents
Módszerek kolesztázisos és fibrotikus betegségek kezeléséreInfo
- Publication number
- HUE052886T2 HUE052886T2 HUE17710285A HUE17710285A HUE052886T2 HU E052886 T2 HUE052886 T2 HU E052886T2 HU E17710285 A HUE17710285 A HU E17710285A HU E17710285 A HUE17710285 A HU E17710285A HU E052886 T2 HUE052886 T2 HU E052886T2
- Authority
- HU
- Hungary
- Prior art keywords
- cholestatic
- treatment
- methods
- fibrotic diseases
- fibrotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305425 | 2016-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE052886T2 true HUE052886T2 (hu) | 2021-05-28 |
Family
ID=55755536
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE20194458A HUE060671T2 (hu) | 2016-04-11 | 2017-03-13 | Eljárás fibrotikus betegségek kezelésére |
| HUE17710285A HUE052886T2 (hu) | 2016-04-11 | 2017-03-13 | Módszerek kolesztázisos és fibrotikus betegségek kezelésére |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE20194458A HUE060671T2 (hu) | 2016-04-11 | 2017-03-13 | Eljárás fibrotikus betegségek kezelésére |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US20170290812A1 (hu) |
| EP (3) | EP3442580B1 (hu) |
| JP (1) | JP6894923B2 (hu) |
| KR (1) | KR102431257B1 (hu) |
| CN (1) | CN109069648B (hu) |
| AU (1) | AU2017249602B2 (hu) |
| CA (1) | CA3019399A1 (hu) |
| DK (2) | DK3777855T3 (hu) |
| EA (2) | EA202191466A1 (hu) |
| ES (3) | ES2928408T3 (hu) |
| HR (1) | HRP20201954T1 (hu) |
| HU (2) | HUE060671T2 (hu) |
| IL (1) | IL262052B (hu) |
| LT (1) | LT3442580T (hu) |
| MD (1) | MD3442580T2 (hu) |
| MX (1) | MX2018012287A (hu) |
| MY (1) | MY195437A (hu) |
| PH (1) | PH12018502142A1 (hu) |
| PL (1) | PL3442580T3 (hu) |
| PT (2) | PT3777855T (hu) |
| SG (2) | SG11201808402RA (hu) |
| SI (1) | SI3442580T1 (hu) |
| WO (1) | WO2017178172A1 (hu) |
| ZA (1) | ZA201807389B (hu) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018012287A (es) | 2016-04-11 | 2019-02-07 | Genfit | Metodos de tratamiento para enfermedades colestasicas y fibroticas. |
| WO2017178174A1 (en) * | 2016-04-11 | 2017-10-19 | Genfit | Methods of treatment of cholestasis and fibrosis |
| WO2018167103A1 (en) * | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| CN110650958A (zh) * | 2017-03-21 | 2020-01-03 | 诺瓦莱德制药公司 | 用于磷酸二酯酶抑制及其相关病症的治疗剂 |
| US11547699B2 (en) | 2017-11-17 | 2023-01-10 | Hubert Köster | [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases |
| EP3639822A1 (en) * | 2018-10-15 | 2020-04-22 | Universität Regensburg | Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion |
| CA3130518A1 (en) * | 2019-04-12 | 2020-10-15 | Nicolas STANKOVIC-VALENTIN | Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress |
| CN110205302B (zh) * | 2019-06-24 | 2021-03-23 | 扬州大学 | 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用 |
| CN110478357A (zh) * | 2019-07-23 | 2019-11-22 | 哈尔滨医科大学 | 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用 |
| CN110368498A (zh) * | 2019-08-26 | 2019-10-25 | 瑞希(重庆)生物科技有限公司 | 一种促进伤口愈合的制剂及其制备方法 |
| CN114630660A (zh) | 2019-10-28 | 2022-06-14 | 基恩菲特公司 | 具有抗氧化特性的联合疗法 |
| CN113398125B (zh) * | 2020-03-16 | 2024-05-03 | 绍兴君科臻元医药科技有限公司 | 替唑尼特药物组合物及其医药用途 |
| US20240000754A1 (en) * | 2020-11-17 | 2024-01-04 | Genfit | Methods of treatment of liver failure |
| WO2022218239A1 (zh) * | 2021-04-12 | 2022-10-20 | 杜心赟 | 新型噻唑类化合物及其制备方法和用途 |
| CN116077502A (zh) * | 2021-11-05 | 2023-05-09 | 广州市妇女儿童医疗中心 | 叶酸在预防、诊断和治疗遗传性、感染性或过敏性疾病中的应用 |
| WO2024074515A1 (en) * | 2022-10-04 | 2024-04-11 | Genfit | Nitazoxanide for the treatment of hepatic impairment |
| CN116911513A (zh) * | 2023-02-07 | 2023-10-20 | 中国药科大学 | 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用 |
| CN117838690A (zh) * | 2023-10-09 | 2024-04-09 | 中国药科大学 | 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| GB1440212A (en) | 1973-08-29 | 1976-06-23 | Phavic Sprl | Derivatives of 2-phenoxyacetamido-5-nitrothiazoles |
| US5968961A (en) | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
| MX9604483A (es) | 1994-09-08 | 1998-02-28 | Jean-Francois Rossignol | Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas. |
| US5965590A (en) | 1994-09-08 | 1999-10-12 | Romark Lab Lc | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
| US5935591A (en) | 1998-01-15 | 1999-08-10 | Romark Laboratories, L.C. | Method for treatment of equine protozoal myeloencephalitis with thiazolides |
| US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| WO2002051442A1 (fr) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Co-prescriptions |
| WO2005026137A2 (en) | 2003-09-06 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| UA90864C2 (en) | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
| AU2006343359A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| EP1971594A2 (en) | 2005-11-21 | 2008-09-24 | Biogen Idec MA Inc. | Substituted pyrazalones |
| DK1976516T3 (da) | 2006-01-09 | 2013-07-15 | Romark Lab Lc | Behandling af viral hepatitis |
| EP1983980A4 (en) | 2006-01-25 | 2010-05-05 | Synta Pharmaceuticals Corp | THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY |
| GB0619500D0 (en) | 2006-10-03 | 2006-11-08 | Univ Keele | Treatment of fibrosis |
| ES2550755T3 (es) | 2007-08-03 | 2015-11-12 | Romark Laboratories, L.C. | Compuestos de tiazolida sustituidos con alquilsulfonilo |
| US20110177999A1 (en) * | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
| KR101045572B1 (ko) | 2007-08-14 | 2011-07-01 | 주식회사 엘지화학 | Ｃｌｏｓｔｒｉｄｉｕｍ ｐｒｏｐｉｏｎｉｃｕｍ 유래의프로피오닐―ＣｏＡ 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법 |
| US9149463B2 (en) * | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| WO2009039248A2 (en) | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection |
| US20100016262A1 (en) | 2007-10-18 | 2010-01-21 | Yale University | Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis |
| EP2408449A4 (en) * | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
| CN105853415A (zh) | 2009-05-12 | 2016-08-17 | 罗马克实验室有限公司 | 卤代烷基杂芳基苯甲酰胺化合物 |
| KR20170141830A (ko) | 2009-06-26 | 2017-12-26 | 로마크 레버러토리즈, 엘.씨. | 인플루엔자를 치료하기 위한 화합물 및 방법 |
| US8816074B2 (en) | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| EA201270632A1 (ru) | 2009-11-16 | 2013-01-30 | Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. | 2'-фтор-6'-метилен карбоциклические нуклеозиды и способы лечения вирусных инфекций |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| EP2566853B1 (en) | 2010-05-05 | 2017-01-25 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| US9079891B2 (en) | 2010-08-27 | 2015-07-14 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2012061190A1 (en) | 2010-11-01 | 2012-05-10 | Romark Laboratories L.C. | Alkylsulfinyl-substituted thiazolide compounds |
| JP6253991B2 (ja) | 2011-03-02 | 2017-12-27 | ジェローム シェンターク， | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
| JP6138764B2 (ja) | 2011-05-16 | 2017-05-31 | ロマーク ラボラトリーズ エル．シー． | ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 |
| US9856240B2 (en) | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2013202269A1 (en) * | 2011-10-26 | 2013-05-16 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| WO2013082469A2 (en) | 2011-12-02 | 2013-06-06 | University Of Vermont And State Agricultural College | Methods and compositions for treating infections |
| CA2922849A1 (en) | 2012-08-31 | 2014-03-06 | Ixchel Pharma, Llc | Agents useful for treating obesity, diabetes and related disorders |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9974767B2 (en) | 2014-07-14 | 2018-05-22 | University Of Washington | Statins in the treatment of muscular dystrophies and myopathies |
| CA2967333A1 (en) | 2014-11-11 | 2016-05-19 | Romark Laboratories, L.C. | Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof |
| WO2016210247A1 (en) | 2015-06-24 | 2016-12-29 | Duke University | New methods of use for an anti-diarrhea agent |
| WO2017178174A1 (en) | 2016-04-11 | 2017-10-19 | Genfit | Methods of treatment of cholestasis and fibrosis |
| MX2018012287A (es) | 2016-04-11 | 2019-02-07 | Genfit | Metodos de tratamiento para enfermedades colestasicas y fibroticas. |
| KR102410951B1 (ko) | 2016-04-11 | 2022-06-20 | 장피트 | 담즙정체성 및 섬유증 질환의 치료 방법 |
-
2017
- 2017-03-13 MX MX2018012287A patent/MX2018012287A/es unknown
- 2017-03-13 WO PCT/EP2017/055878 patent/WO2017178172A1/en active Application Filing
- 2017-03-13 PL PL17710285T patent/PL3442580T3/pl unknown
- 2017-03-13 PT PT201944584T patent/PT3777855T/pt unknown
- 2017-03-13 US US15/457,158 patent/US20170290812A1/en not_active Abandoned
- 2017-03-13 CN CN201780023160.XA patent/CN109069648B/zh active Active
- 2017-03-13 JP JP2018553102A patent/JP6894923B2/ja active Active
- 2017-03-13 SG SG11201808402RA patent/SG11201808402RA/en unknown
- 2017-03-13 EA EA202191466A patent/EA202191466A1/ru unknown
- 2017-03-13 DK DK20194458.4T patent/DK3777855T3/da active
- 2017-03-13 MD MDE20190213T patent/MD3442580T2/ro unknown
- 2017-03-13 LT LTEP17710285.2T patent/LT3442580T/lt unknown
- 2017-03-13 SG SG10202004425XA patent/SG10202004425XA/en unknown
- 2017-03-13 EA EA201892298A patent/EA201892298A1/ru unknown
- 2017-03-13 AU AU2017249602A patent/AU2017249602B2/en active Active
- 2017-03-13 KR KR1020187032681A patent/KR102431257B1/ko active IP Right Grant
- 2017-03-13 HU HUE20194458A patent/HUE060671T2/hu unknown
- 2017-03-13 MY MYPI2018001719A patent/MY195437A/en unknown
- 2017-03-13 HU HUE17710285A patent/HUE052886T2/hu unknown
- 2017-03-13 SI SI201730549T patent/SI3442580T1/sl unknown
- 2017-03-13 ES ES20194454T patent/ES2928408T3/es active Active
- 2017-03-13 PT PT177102852T patent/PT3442580T/pt unknown
- 2017-03-13 EP EP17710285.2A patent/EP3442580B1/en active Active
- 2017-03-13 ES ES17710285T patent/ES2839453T3/es active Active
- 2017-03-13 EP EP20194458.4A patent/EP3777855B1/en active Active
- 2017-03-13 DK DK17710285.2T patent/DK3442580T3/da active
- 2017-03-13 CA CA3019399A patent/CA3019399A1/en active Pending
- 2017-03-13 EP EP20194454.3A patent/EP3777854B1/en active Active
- 2017-03-13 ES ES20194458T patent/ES2935185T3/es active Active
- 2017-12-11 US US15/837,889 patent/US10130612B2/en active Active
- 2017-12-14 US US15/841,981 patent/US10117856B2/en active Active
- 2017-12-14 US US15/841,777 patent/US10117855B2/en active Active
- 2017-12-14 US US15/842,234 patent/US10130613B2/en active Active
-
2018
- 2018-09-19 US US16/135,945 patent/US20190000813A1/en not_active Abandoned
- 2018-10-02 IL IL262052A patent/IL262052B/en unknown
- 2018-10-04 PH PH12018502142A patent/PH12018502142A1/en unknown
- 2018-11-05 ZA ZA2018/07389A patent/ZA201807389B/en unknown
-
2020
- 2020-06-24 US US16/910,756 patent/US11103484B2/en active Active
- 2020-12-07 HR HRP20201954TT patent/HRP20201954T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807389B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| ZA202006746B (en) | Methods of treatment | |
| HK1246179A1 (zh) | 治療視網膜疾病的方法 | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| HRP20181914T1 (hr) | Liječenje intrahepatičnih kolestatskih bolesti | |
| ZA201807390B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| IL274541A (en) | A method for treating diseases of the digestive tract using Tradifitant | |
| HK1258994A1 (zh) | 用於疾病治療的方法 | |
| ZA201808360B (en) | Treatment of intrahepatic cholestatic diseases | |
| IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
| HK1255691A1 (zh) | 對疾病進行組織學診斷和治療的方法 | |
| HK1245671A1 (zh) | 使用白細胞介素-10治療疾病和病症的方法 | |
| HK1243937A1 (zh) | 治療疾病的方法 | |
| EP3151824A4 (en) | Methods of treating neurodevelopmental diseases and disorders | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| GB201500555D0 (en) | Method and device for the treatment of diseases | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer | |
| GB201414023D0 (en) | Treatment of autoimmune diseases | |
| AU2014902173A0 (en) | Methods of treating neurodevelopmental diseases and disorders |